Plunkett's Biotech & Genetics Industry Almanac 2018

Jack W. Plunkett is CEO & Publisher of Plunkett Research, Ltd., a Houston-based provider of market research and industry information in printed and electronic formats. Plunkett Research provides analysis, statistics and other vital data on all major industry sectors, from InfoTech to Retailing to Banking and Nanotechnology. Plunkett's client list includes 10,000 leading corporations, universities and government agencies worldwide. Plunkett's research products are distributed electronically through subscriptions to its website and around the globe by major booksellers and news distributors, including Bloomberg and ThomsonReuters. Jack Plunkett is the author of numerous books, including The Next Boom: What you absolutely, positively have to know about the world between now and 2025. This book won a 2011 gold medal in the Business Book Awards competition sponsored by Axiom and INC Magazine. Plunkett is frequently interviewed as an expert source by publications such as Time magazine, The Wall Street Journal, The New York Times and Investor's Business Daily, media outlets such as NPR's Marketplace, ABC, and CBS Marketwatch, as well as local and regional newspapers and national columnists. Plunkett received an Academic Book of the Year Award for his Plunkett’s Health Care Industry Almanac, and he was a regional finalist in the Entrepreneur of the Year Awards sponsored by Ernst & Young.

Introduction 1
How to Use This Book 3
Chapter 1: Major Trends Affecting the Biotech & Genetics Industry 7
1) The State of the Biotechnology Industry Today 7
2) A Short History of Biotechnology 11
3) Ethanol Production Soared, But U.S. Federal Subsidy Expires 13
4) Cellulosic Ethanol Makes Slow Commercial Progress 14
5) Major Drug Companies Acquire or Partner With Smaller Biotech Firms 15
6) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development 15
7) Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance 17
8) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing 19
9) Vaccines and Viruses in Drug Delivery 20
10) New Blockbuster Drugs Come to Market/ Drug Prices Soar 20
11) Generic Drugs Have Biggest Market Share by Unit Volume, but not by Total Revenues 22
12) Coupons and Other Marketing Schemes Obscure the Retail Prices of Drugs in the U.S., Which Are Vastly Higher than Prices Paid in Other Nations 22
13) Biotech and Orphan Drugs Create New Revenues for Drug Firms 24
14) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce 24
15) Stem Cells—Multiple Sources Stem from New Technologies 26
16) Government Support for Stem Cell Research Evolves 26
17) Stem Cells—Therapeutic Cloning Techniques Advance 27
18) Stem Cells—A New Era of Tissue Replacement Takes Shape 28
19) Nanotechnology Converges with Biotech 29
20) Genetically Modified (GM) Seeds and Crops Planted in Dozens of Nations/Agribio R&D Investment Is High 30
21) Genetically Modified (GM) Foods Prompt Controversy, Labeling and Legislation 32
22) Cloning of Farm Animals/Meat and Cheese Substitutes Created in Laboratories/3-D Printed Food Appears 33
23) Selective Breeding, Zinc Fingers, Mutagenesis and Gene-Editing as Alternatives to GMOs 33
24) Immunotherapy Promises New Approach to Fighting Cancers 34
25) Technology Discussion—Genes and DNA 35
26) Technology Discussion—Proteins and Proteomics 36
27) Technology Discussion—DNA Chips 36
28) Technology Discussion—SNPs (“Snips”) 37
29) Technology Discussion—Synthetic Biology 37
30) Technology Discussion—Recombinant DNA 38
31) Technology Discussion—Polymerase Chain Reaction (PCR) 38
Chapter 2: Biotech & Genetics Industry Statistics 39
Biotech Industry Statistics and Market Size Overview 40
The U.S. Drug Discovery & Approval Process 41
U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2016 42
U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2016 43
Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2016 44
Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2015-2017 45
U.S. Exports & Imports of Pharmaceutical Products: 2011-1st Quarter 2017 46
U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2009-2025 47
Prescription Drug Expenditures, U.S.: Selected Years, 1965-2025 49
Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2015 50
Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2016-2018 51
Global Area of Biotech Crops by Country: 2016 52
Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1980-2015 53
Sales By Geographic Area, PhRMA Member Companies: 2014 54
Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1980-2015 55
Domestic U.S. Biopharmaceutical R&D & R&D Abroad Breakdown, PhRMA Member Companies: 2014 56
Chapter 3: Important Biotech & Genetics Industry Contacts 57
(Addresses, Phone Numbers and Internet Sites)
Chapter 4: THE BIOTECH 400: Who They Are and How They Were Chosen 95
Index of Companies Within Industry Groups 96
Alphabetical Index 105
Index of U.S. Headquarters Location by State 108
Index of Non-U.S. Headquarters Location by Country 111
Individual Profiles on Each of THE BIOTECH 400 115
Additional Indexes
Index of Hot Spots for Advancement for Women/Minorities 498
Index by Subsidiaries, Brand Names and Selected Affiliations 500
A Short Biotech & Genetics Industry Glossary 519